Our team envisioned a better patient journey for orthopedic surgery procedures as well as the deep brain stimulation program. FHIR and our relationship with Rimidi brought that vision to life.
February 23, 2021
Today, Atlanta-based organizations Rimidi, a cloud-based software platform that enables personalized management of health conditions across populations, and Emory Healthcare, the most comprehensive academic healthcare system in the state of Georgia, have announced a strategic collaboration designed to further enhance innovation in the healthcare arena.
As an immediate result of the collaboration, Rimidi and Emory Healthcare have developed new patient and provider-facing Fast Healthcare Interoperable Resource or FHIR apps to create a more collaborative and transparent experience for patients undergoing orthopedic surgery, as well as for those referred to the deep brain stimulation (DBS) program for Parkinson’s and other neurologic conditions at Emory Healthcare. Connecting to patients across the continuum of care from home to the clinic to the operating room is essential for driving patient-centered care. These apps bring together clinical data and protocols with patient reported outcomes and education in the context of the patient journey.
“Perioperative care involves many complex, multi-step processes that can be daunting for the patient and inefficient for the clinical staff. By marrying Rimidi’s leading healthcare technology software with Emory’s clinical thought leadership, we’ve identified new ways to enhance the patient experience and improve clinical efficiency,” said Lucienne Ide, MD, PhD, founder of Rimidi.
As early pioneers of SMART on FHIR, Rimidi’s apps work directly within leading EHR’s – no separate sign in, no workflow disruption and better clinical efficiency. Rimidi combines patient-generated health data from connected devices or patient reported outcomes measures with clinical data to drive patient-specific clinical insights and actions through embedded clinical decision support pathways.
Ortho on FHIR delivers a better overall orthopedic surgery experience, enabling providers to document procedure detail and track outcomes with integration to surgical and clinical schedules. With the app, surgeons also gain the ability to one touch dial to call patients post-operatively, view results of patient reported outcomes, such as nausea, pain, medication usage, and physical therapy outcomes, and search by patient, procedure, or multiple patient characteristics to find patients with similar cases to compare therapy regimens.
Additionally, DBS on FHIR enhances the entire patient journey, guiding patients from referral to post-surgical care, providing transparency in the process. The app enables patients to view appointments straight from their phone, communicate with and receive reminders from their clinical care team and access and complete patient education. Simultaneously, providers can leverage the app to enroll patients, configure specific surgical pathways and pre-surgical actions and arrival times, ensure patients have acknowledged medication-off reminders, and more.
“Our team envisioned a better patient journey for orthopedic surgery procedures as well as the deep brain stimulation program. FHIR and our relationship with Rimidi brought that vision to life,” said Scott D. Boden, MD, vice president for business innovation at Emory Healthcare. “We look forward to working with Rimidi on developing additional apps in other areas to continuously improve the patient experience and health outcomes.”
In addition to working with Rimidi on the FHIR apps, Emory Healthcare also leverages Rimidi’s clinical management platform to manage high acuity patients with chronic cardiometabolic conditions.
Rimidi’s new FHIR-based Ortho and Deep Brain Stimulation Apps are currently implemented at Emory, and are now commercially available for additional leading hospitals and health systems across the U.S. For more information and for forthcoming updates on additional app use cases, visit http://www.rimidi.com and follow @Jointherimidi on social media.
Share article on social media or email: